Tags

Type your tag names separated by a space and hit enter

A 10-year single-center experience on Stenotrophomonas maltophilia resistotyping in Szeged, Hungary.
Eur J Microbiol Immunol (Bp). 2020 Apr 23 [Online ahead of print]EJ

Abstract

Stenotrophomonas maltophilia is an aerobic, oxidase-negative and catalase-positive bacillus. S. maltophilia is a recognized opportunistic pathogen. Due to the advancements in invasive medical procedures, organ transplantation and chemotherapy of malignant illnesses, the relevance of this pathogen increased significantly. The therapy of S. maltophilia infections is challenging, as these bacteria show intrinsic resistance to multiple classes of antibiotics, the first-choice drug is sulfamethoxazole/trimethoprim. Our aim was to assess the epidemiology of S. maltophilia from various clinical samples and the characterization of resistance-levels and resistotyping of these samples over a long surveillance period. The study included S. maltophilia bacterial isolates from blood culture samples, respiratory samples and urine samples and the data for the samples, received between January 2008 until December 2017, a total of 817 S. maltophilia isolates were identified (respiratory samples n = 579, 70.9%, blood culture samples n = 175, 21.4% and urine samples n = 63, 7.7%). Levofloxacin and colistin-susceptibility rates were the highest (92.2%; n = 753), followed by tigecycline (90.5%, n = 739), the first-line agent sulfamethoxazole/trimethoprim (87.4%, n = 714), while phenotypic resistance rate was highest for amikacin (72.5% of isolates were resistant, n = 592). The clinical problem of sulfamethoxazole/trimethoprim-resistance is a complex issue, because there is no guideline available for the therapy of these infections.

Authors+Show Affiliations

1Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Eötvös utca 6., 6720, Szeged,Hungary.2Department of Public Health, Faculty of Medicine, University of Szeged, Dóm tér 10., 6720, Szeged,Hungary.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32590357

Citation

Gajdács, Márió, and Edit Urbán. "A 10-year Single-center Experience On Stenotrophomonas Maltophilia Resistotyping in Szeged, Hungary." European Journal of Microbiology & Immunology, 2020.
Gajdács M, Urbán E. A 10-year single-center experience on Stenotrophomonas maltophilia resistotyping in Szeged, Hungary. Eur J Microbiol Immunol (Bp). 2020.
Gajdács, M., & Urbán, E. (2020). A 10-year single-center experience on Stenotrophomonas maltophilia resistotyping in Szeged, Hungary. European Journal of Microbiology & Immunology. https://doi.org/10.1556/1886.2020.00006
Gajdács M, Urbán E. A 10-year Single-center Experience On Stenotrophomonas Maltophilia Resistotyping in Szeged, Hungary. Eur J Microbiol Immunol (Bp). 2020 Apr 23; PubMed PMID: 32590357.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A 10-year single-center experience on Stenotrophomonas maltophilia resistotyping in Szeged, Hungary. AU - Gajdács,Márió, AU - Urbán,Edit, Y1 - 2020/04/23/ PY - 2020/02/25/received PY - 2020/03/01/accepted PY - 2020/6/27/entrez PY - 2020/6/27/pubmed PY - 2020/6/27/medline KW - Stenotrophomonas maltophilia KW - levofloxacin KW - resistance KW - resistotype KW - sulfamethoxazole/trimethoprim JF - European journal of microbiology & immunology JO - Eur J Microbiol Immunol (Bp) N2 - Stenotrophomonas maltophilia is an aerobic, oxidase-negative and catalase-positive bacillus. S. maltophilia is a recognized opportunistic pathogen. Due to the advancements in invasive medical procedures, organ transplantation and chemotherapy of malignant illnesses, the relevance of this pathogen increased significantly. The therapy of S. maltophilia infections is challenging, as these bacteria show intrinsic resistance to multiple classes of antibiotics, the first-choice drug is sulfamethoxazole/trimethoprim. Our aim was to assess the epidemiology of S. maltophilia from various clinical samples and the characterization of resistance-levels and resistotyping of these samples over a long surveillance period. The study included S. maltophilia bacterial isolates from blood culture samples, respiratory samples and urine samples and the data for the samples, received between January 2008 until December 2017, a total of 817 S. maltophilia isolates were identified (respiratory samples n = 579, 70.9%, blood culture samples n = 175, 21.4% and urine samples n = 63, 7.7%). Levofloxacin and colistin-susceptibility rates were the highest (92.2%; n = 753), followed by tigecycline (90.5%, n = 739), the first-line agent sulfamethoxazole/trimethoprim (87.4%, n = 714), while phenotypic resistance rate was highest for amikacin (72.5% of isolates were resistant, n = 592). The clinical problem of sulfamethoxazole/trimethoprim-resistance is a complex issue, because there is no guideline available for the therapy of these infections. SN - 2062-509X UR - https://www.unboundmedicine.com/medline/citation/32590357/A_10-year_single-center_experience_on_Stenotrophomonas_maltophilia_resistotyping_in_Szeged,_Hungary L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32590357/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.